Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuron Limited - American Depositary Shares (NQ:IMRN)

0.7551 +0.0014 (+0.19%)
Streaming Delayed Price Updated: 2:55 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immuron Limited - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target
Via ACCESS Newswire
News headline image
Immuron Reports Continued Sales Growth
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron New U.S. Department of Defense Award & Clinical Trial Update
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron IMM-529 IND approved by FDA
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Announces Clinical Trial Update
From Immuron Limited
Via GlobeNewswire
News headline image
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on... 
Via Newsfile
News headline image
Immuron Q1 FY26 YoY growth
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Submits IMM-529 IND to FDA
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Letter to Shareholders – Projects Update
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron partners with InvestorHub
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron - FY25 global sales exceed projection, up 49% on prior year
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Letter to Shareholders: Projects Update
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Travelan® highest sales in history
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Travelan® continued strong sales growth
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Announces Travelan® Clinical Trial Update
From Immuron Limited
Via GlobeNewswire
News headline image
UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
Via ACCESSWIRE
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event
Via ACCESSWIRE
News headline image
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Travelan® continued strong sales growth
From Immuron Limited
Via GlobeNewswire
News headline image
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
From Immuron Limited
Via GlobeNewswire
News headline image
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
From Immuron Limited
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.